Madelyn D. Purcell Portfolio
Invests via Pfizer Inc | Managed by Madelyn D. Purcell
Invests via Pfizer Inc
Managed by Madelyn D. Purcell
Automatically Tracked
Madelyn D. Purcell Profile
Madelyn D. Purcell is a prominent investor-operator with extensive experience in private equity and venture capital. She has played crucial roles in identifying and nurturing growth-stage companies across technology and healthcare sectors, leveraging her background in corporate finance to drive operational efficiency. Her insight into market trends positions her as a strategic leader who bridges the gap between capital allocation and entrepreneurial execution. With an educational foundation in business administration, she remains actively engaged in mentoring emerging leaders within her network while also championing innovative projects that contribute to industry advancements.
Madelyn D. Purcell is a prominent investor-operator with extensive experience in private equity and venture capital. She has played crucial roles in identifying and nurturing growth-stage companies across technology and healthcare sectors, leveraging her background in corporate finance to drive operational efficiency. Her insight into market trends positions her as a strategic leader who bridges the gap between capital allocation and entrepreneurial execution. With an educational foundation in business administration, she remains actively engaged in mentoring emerging leaders within her network while also championing innovative projects that contribute to industry advancements.
Investment Philosophy & Strategy
Growth opportunities in emerging markets capture attention as Madelyn D. Purcell combines her operational expertise with a keen understanding of investment dynamics. Her strategic mindset drives her to seek transformative ventures, especially within technology and healthcare realms where innovation flourishes. By focusing on the scalability of businesses, she identifies potential for significant impact and sustainable returns. Active involvement in mentoring highlights her commitment to cultivating the next generation of leaders, which complements her hands-on approach to enhancing company performance. This intersection of insight and execution allows for agile decision-making aligned with long-term aspirations.
Growth opportunities in emerging markets capture attention as Madelyn D. Purcell combines her operational expertise with a keen understanding of investment dynamics. Her strategic mindset drives her to seek transformative ventures, especially within technology and healthcare realms where innovation flourishes. By focusing on the scalability of businesses, she identifies potential for significant impact and sustainable returns. Active involvement in mentoring highlights her commitment to cultivating the next generation of leaders, which complements her hands-on approach to enhancing company performance. This intersection of insight and execution allows for agile decision-making aligned with long-term aspirations.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
4.11%
Gain +0.03%
Monthly
0.2%
Yearly
2.4%
Drawdown
9.19%
$157.45M
Equity
Holdings
$157.45M
Investment
$199.04M
$106.3M
Profit +$716,776.08
Realized
$147.9M
Unrealized
-$41.6M
Dividends
$0
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
0.03%
Profit
$716,776.08
Win %
47%
This Week
Compared To Last Week
Gain
-9.94%
Profit
-$17.37M
Win %
47%
This Month
Compared to last month
Gain
-6.03%
Profit
-$10.11M
Win %
47%
This Year
Compared to last year
Gain
-2.48%
Profit
-$4.01M
Win %
59%
NXTC NextCure, Inc.
+4.24%
+$13,747.57 
BHVN Biohaven Ltd.
+2.5%
+$161,806.4 
ORIC Oric Pharmaceuticals Inc.
+2.45%
+$110,267.71 
ZURA Zura Bio Ltd.
+2.42%
+$70,049.33 
SPRO Spero Therapeutics Inc.
+1.43%
+$37,797.57 
CELC Celcuity Inc.
+1.14%
+$288,260.7 
SENS Senseonics Holdings, Inc.
+0.85%
+$162.82 
CRBU Caribou Biosciences, Inc.
+0.73%
+$46,904.31 
ALLO Allogene Therapeutics Inc.
+0.57%
+$220,320.4 
ARVN Arvinas Inc.
+0.23%
+$69,156.3 
BOLT Bolt Biotherapeutics Inc.
0%
$0 
ZNTL Zentalis Pharmaceuticals, Inc.
0%
$0 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 38 | Longs Won 18/38 47% | Profit Factor 1.76 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $26.97M |
| Average Win $13.65M | Best Trade (Mar 30) $147.92M | Sharpe Ratio -67.47 |
| Average Loss -$6.97M | Worst Trade (Sep 10) -$36.79M | Z-Score -0.15 (11.73%) |
| Commissions $0 | Avg. Trade Length 1y 2m 1w | Expectancy $2.8M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | 7.87% | 16.92% | 26.47% | 36.36% | 46.52% | 56.89% | 67.45% | 78.16% | 89.02% |
| Consecutive Losing Trades | 23 | 20 | 18 | 16 | 14 | 11 | 9 | 7 | 5 | 2 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
 AGMB Agomab Therapeutics NV | 75,000 | $813,750 | $1.03M | - | $220,500 | 27.1% | -1.076% |
| ALLO Allogene Therapeutics Inc. | 22.03M | $46.93M | $39M | - | -$7.93M | -16.9% | +0.568% |
| ARVN Arvinas Inc. | 3.46M | $66.29M | $30.19M | - | -$36.1M | -54.46% | +0.23% |
| BHVN Biohaven Ltd. | 505,645 | $18.89M | $6.63M | - | -$12.26M | -64.9% | +2.502% |
| BOLT Bolt Biotherapeutics Inc. | 31,305 | $180,630 | $116,767.65 | - | -$63,862.35 | -35.36% | 0.0 |
| CELC Celcuity Inc. | 295,652 | $3.87M | $25.56M | - | $21.69M | 560.54% | +1.14% |
| CRBU Caribou Biosciences, Inc. | 4.69M | $7.46M | $6.47M | - | -$984,990.04 | -13.21% | +0.73% |
 CRDF Cardiff Oncology Inc. | 2.41M | $10.47M | $2.86M | - | -$7.61M | -72.7% | -2.066% |
 DNA Ginkgo Bioworks Holdings Inc. | 2,928 | $28,754 | $19,427.28 | - | -$9,326.72 | -32.44% | -2.139% |
| NXTC NextCure, Inc. | 44,347 | $259,873.54 | $337,924.14 | - | $78,050.6 | 30.03% | +4.241% |
| ORIC Oric Pharmaceuticals Inc. | 372,904 | $3.01M | $4.61M | - | $1.6M | 53.23% | +2.45% |
 PYXS Pyxis Oncology, Inc. | 7.03M | $10.97M | $22.79M | - | $11.82M | 107.69% | -0.917% |
| SENS Senseonics Holdings, Inc. | 2,171 | $22,726.03 | $19,245.91 | - | -$3,480.12 | -15.31% | +0.853% |
| SPRO Spero Therapeutics Inc. | 2.36M | $2.43M | $2.68M | - | $250,409.36 | 10.29% | +1.429% |
 WVE Wave Life Sciences Ltd. | 1.88M | $23.19M | $8.74M | - | -$14.46M | -62.33% | -0.214% |
| ZNTL Zentalis Pharmaceuticals, Inc. | 953,834 | $2.89M | $3.42M | - | $534,147.04 | 18.48% | 0.0 |
| ZURA Zura Bio Ltd. | 538,841 | $1.35M | $2.97M | - | $1.62M | 120.4% | +2.416% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Madelyn D. Purcell?
The largest contributions to the portfolio's profits come from the following stocks: Haleon Plc - ADR - $147.92M, Tourmaline Bio Inc - $35.05M, Oric Pharmaceuticals Inc - $11.57M, Zura Bio Ltd - $7M, and Celcuity Inc - $5.43M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: BioNTech SE - $56.08M, Essa Pharma Inc - $2.68M, NextCure, Inc - $889,443.25, AN2 Therapeutics, Inc - $171,671.01, and BOLT - $84,587.01. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are Madelyn D. Purcell's monthly returns?
Madelyn D. Purcell's monthly returns look fairly stable overall, although some fluctuations are still visible. The performance pattern suggests a strategy that remains reasonably controlled from month to month, even if it is not completely smooth. This may appeal to users looking for a balance between steadier results and meaningful upside potential.
Can Madelyn D. Purcell's strategy be considered aggressive or moderate?
Madelyn D. Purcell's strategy leans toward a moderately conservative profile. While there is still some exposure to market fluctuations, the overall structure and risk levels suggest a focus on maintaining stability rather than pursuing aggressive growth.
Should beginners follow Madelyn D. Purcell's strategy?
Madelyn D. Purcell's strategy appears suitable for beginners. The overall risk level, structure, and behavior of the portfolio suggest a relatively manageable approach that does not rely on extreme volatility or complex positioning. This makes it easier for less experienced users to understand and potentially follow.
